It is possible that upregulation of ESRP1 expression not only inhibits EMT, but also induces G1-phase arrest in cancer cells, and thus ESRP1 is likely to be an ideal candidate target for anti-cancer drugs, although more experiments will be needed to support this hypothesis. The gene discussed is ESRP1; the disease is cancer.